ClinicalTrials.gg
RecruitingNCT05638867Updated Aug 11, 2026

NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

A Phase 4 interventional study of Aspirin + Clopidogrel + Rivaroxaban and Aspirin + Clopidogrel in Coronary Artery Disease, Percutaneous Coronary Intervention and Acute Coronary Syndrome, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by China National Center for Cardiovascular Diseases · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,944
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies testing aspirin in Coronary Artery Disease — 8 open to participants now, 9 under way, 1 of them phase 3. Aspirin · Coronary Artery Disease.

Planned enrollment
5th of 53
3,944 · median 200
Started
2023
with 1 other
Phase 4
38 of 53
5 open now
Registered
49th of 53
by date

Among the 53 studies testing aspirin in Coronary Artery Disease, this one is the 5th largest by planned enrollment, is one of 2 that started in 2023, is one of 38 in phase 4, and was the 49th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 53 studies testing aspirin in Coronary Artery Disease are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aspirin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk. The main questions it aims to answer are:

  • Whether the intervention is effective in reducing ischemic events
  • Whether the intervention is safe from increasing bleeding events, especially severe or fatal ones

Participants will be randomized to receive standard DAPT therapy for the entire study duration or low-dose rivaroxaban+DAPT for 3 months, followed by standard DAPT for the rest of the study duration. Patients enrolled should complete 5 follow-ups in the form of clinic visit or telephone call.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • Acute Coronary Syndrome

Keywords

  • Novel Oral Anticoagulant
  • PARIS risk score
  • D-dimer
  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with Acute Coronary Syndrome 1-7 days after initial symptom stabilization,
  • Aged 18-75 years old,
  • Elevated D-dimer levels (≥0.28 μg/ml) on admission or PARIS coronary thrombosis risk score ≥ 3 points,
  • Received Percutaneous Coronary Intervention and not on non-oral anticoagulants,
  • Indicated for dual antiplatelet medication

Exclusion criteria

Exclusion Criteria:

  • level below 90 x10\^6
  • level is less than 11g/dL
  • History of severe bleeding
  • History of stroke/
  • Severe hepatic/renal insufficiency
  • Indicated for anticoagulation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3,944 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Triple Antithrombotic Therapy: Aspirin (12 months) + Clopidogrel (12 months) + Rivaroxaban (3 months)

    Drug: Aspirin + Clopidogrel + Rivaroxaban

  • Other
    Control Group

    Dual Antiplatelet Therapy: Aspirin (12 months) + Clopidogrel (12 months)

    Drug: Aspirin + Clopidogrel

Interventions

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

    Composite events including all-cause death, myocardial infarction, stroke, ischemia-driven revascularization, stent thrombosis, and systemic embolism

    Time frame: 12 months

Secondary outcomes

  1. All-cause Death

    Time frame: 12 months

  2. Cardiac Death

    Time frame: 12 months

  3. Myocardial Infarction

    Time frame: 12 months

  4. Stroke

    Time frame: 12 months

  5. Ischemia-driven Revascularization

    Time frame: 12 months

  6. Stent Thrombosis

    Time frame: 12 months

  7. Systemic Embolism

    Time frame: 12 months

  8. Net Adverse Clinical Events

    Composite events including MACCE and bleeding

    Time frame: 12 months

Other outcomes

  1. Bleeding

    BARC 3,5 bleeding events

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jia S, Song Y, Yuan D, Wang P, Xu J, Chen Y, Zhang C, Zhao X, Yuan JQ. PARIS coronary thrombosis risk score combined with D-dimer to guide new oral anticoagulant antithrombotic therapy in patients with acute coronary syndrome after percutaneous coronary intervention: study protocol for the PRIDE-ACS trial. BMJ Open. 2025 May 15;15(5):e090126. doi: 10.1136/bmjopen-2024-090126. PubMed 40379336 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 37 months is close to that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2022
First posted
Dec 6, 2022
StartActual
Nov 25, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05638867
Responsible party
Jinqing Yuan (Deputy Director of Coronary Heart Disease Center, Director of Ward 1, China National Center for Cardiovascular Diseases) — Principal investigator
First posted
Dec 6, 2022
Start date
Nov 25, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

Jinqing Yuan, MD
Contact
dr_jinqingyuan@sina.com
+86-10-68314466
Jinqing Yuan, MD
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Clopidogrel · Rivaroxaban

Start the discussion